Circulation: Cardiovascular quality and outcomes journal report AMERICAN HEART ASSOCIATION DALLAS, June 23, 2020 — Heart failure posed the greatest 5-year risk of death for people newly diagnosed with Type 2 diabetes than any other heart or kidney diseases, according to new research published today in Circulation: Cardiovascular Quality and Outcomes, an American Heart Association...
Tag: <span>pharmaceutical</span>
Post
Solubilizer Captisol enables body to absorb authorized COVID-19 drug therapy
RENDERING OF THE MOLECULAR STRUCTURE OF CAPTISOL, THE SOLUBILIZER INVENTED AT THE UNIVERSITY OF KANSAS, WHICH ALLOWS REMDESIVIR TO BE ADMINISTERED TO THE PATIENT. REMDESIVIR WAS RECENTLY AUTHORIZED UNDER AN… view more CREDIT: VALENTINO STELLA, UNIVERSITY DISTINGUISHED PROFESSOR EMERITUS AT KU LAWRENCE — When the Food and Drug Administration issued an emergency-use authorization for the...
Post
Court strikes down Trump rule that drugmakers disclose price
In a major legal setback for President Donald Trump on a high-profile consumer issue, a federal appeals court has ruled that his administration lacks the legal authority to force drug companies to disclose prices in their TV ads. The ruling denies Trump an easy-to-understand win on a major reelection priority for the White House, bringing...
Post
Novel antisense drug shows promise in slowing fatty liver disease
In Phase II trial, treatment inhibited key enzyme, resulting in lowered triglyceride production and slower progression of non-alcoholic fatty liver disease to its more dangerous form: non-alcoholic steatohepatitis UNIVERSITY OF CALIFORNIA – SAN DIEGO Using a first-of-its-class drug in a clinical trial, an international research effort headed by a scientist at University of California San...
Post
FDA approves Farxiga for heart failure with reduced ejection fraction
The U.S. Food and Drug Administration has granted approval for Farxiga (dapagliflozin) oral tablets to treat adults with heart failure with reduced ejection fraction, the agency announced Tuesday. Farxiga is the first approved sodium-glucose cotransporter 2 inhibitor to treat adults with New York Heart Association functional class II to IV heart failure with reduced ejection...
Post
CAN ALGAE-BASED NASAL SPRAY PREVENT COVID-19?
A nasal spray derived from algae and a plant in the tobacco family could offer a preventive measure for COVID-19, according to a new study. Researchers are making a molecule called Q-griffithsin using an anti-viral protein found in the New Zealand red algae Griffithsia and Nicotiana benthamiana, a plant in the same family as tobacco...
Post
Immunotherapy before surgery could advance care of an aggressive form of skin cancer
In what is believed to be a first-of-its-kind study to evaluate the safety of a type of immunotherapy before surgery in patients with an aggressive form of skin cancer, researchers report that the treatment eliminated pathologic evidence of cancer in nearly half of the study participants undergoing surgery. In patients whose tumors respond, this treatment...
Post
Clinical trial in COVID-19 patients tests anti-inflammatory drug
by The Scripps Research Institute An anti-inflammatory drug developed at Scripps Research 25 years ago is now being tested as a way to prevent acute respiratory distress in patients with COVID-19, the pandemic disease caused by the novel coronavirus. The drug, a monoclonal antibody now owned by the pharmaceutical company Implicit Bioscience, is planned to...
Post
Arteries respond in opposite ways for males and females – pharmaceutical
CREDIT: COPYRIGHT UC REGENTS/UC DAVIS HEALTH A protein known to expand blood vessels — key to controlling conditions like high blood pressure — actually has different functions in males and females, new UC Davis Health research shows. Conducted using arterial cells from mice, the study is the first to identify sex-based distinctions in how the...
Post
Clascoterone cream safe, effective for acne treatment
Adelaide Hebert, M.D., from the University of Texas Health Science Center in Houston, and colleagues assessed the safety and efficacy of clascoterone cream, 1 percent, a novel topical androgen receptor inhibitor, in two phase 3 clinical trials (including a total 1,440 patients) in which patients were randomly assigned to clascoterone cream, 1 percent, or a...